Cargando…
Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy
Glioblastoma multiforme (GBM) is the deadliest and the most heterogeneous brain cancer. The median survival time of GBM patients is approximately 8 to 15 months after initial diagnosis. GBM development is determined by numerous signaling pathways and is considered one of the most challenging and com...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138518/ https://www.ncbi.nlm.nih.gov/pubmed/35625738 http://dx.doi.org/10.3390/biomedicines10051001 |